JPMorgan Equity Premium Income ETF vs Oruka Therapeutics Inc. Common Stock — how do they compare? JPMorgan Equity Premium Income ETF trades at $56.74 (market cap $45.69B), while Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.18B). The key difference: JPMorgan Equity Premium Income ETF is far larger — about 8.8× Oruka Therapeutics Inc. Common Stock's market cap, and Oruka Therapeutics Inc. Common Stock is trading nearer its 52-week high, JPMorgan Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Equity Premium Income ETF for 58 Days and Oruka Therapeutics Inc. Common Stock for 0 Days on average.
| JEPI | ORKA | |
|---|---|---|
Market Cap | $45.69B | $5.18B |
Volume | 3,633,306 | 490,798 |
Sector | Income / Options Overlay | Health |
52-Week High | $59.88 | $113.08 |
52-Week Low | $55.29 | $26.19 |
Typical Hold Time | 58 Days | 0 Days |
Enterprise Value | — | $4.31B |
Signals from Pluang's Aura AI — not financial advice
JEPI trades at $56.93 with minimal daily movement (-0.05%) and maintains a bullish technical outlook based on moving averages. The ETF continues its consistent dividend distribution strategy with recent payments of $0.37 per share. Technical indicators show mixed signals with RSI levels ranging from neutral to overbought, while the overall trend remains positive.
The covered-call strategy provides income stability but may limit upside during strong market rallies. Recent media coverage highlights JEPI's role in retirement income strategies, though investors should consider tax implications and income limitations compared to pure equity exposure.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →